EZH2 and Miyoshi myopathy: We present epigenetic inhibitors as a novel therapeutic intervention for MM by further highlighting the potential use of BMI-1 inhibitors alone or in combination with other epigenetic inhibitors directed to PRC2/EZH2 or BET bromodomains in targeting the malignant MM cell.